CANADIAN CANCER TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA
CHELSEA HOTEL, TORONTO, ON
ROOM: WREN

SATURDAY APRIL 29TH, 2017: 10:00 AM – 3:45 PM

CHAIR: K. CHI
SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO
STUDY COORDINATORS: ALEXANDER MONTENEGRO & PAUL STOS
(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

− To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
− To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
− To update, review, and discuss recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

10:00 am WELCOME

10:05 am Plenary Presentation: Novel Approaches to the Treatment of Urothelial Carcinoma.
Dr. Jonathan Rosenberg

CCTG Lead OPEN TRIALS

10:40 am IND.223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer

IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer

PR.19: A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer.

continued on next page …
CCTG Lead CLOSED TRIALS

10:55 am PR.15 HDR Brachytherapy in Intermediate Risk CaP
   BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma
   E. Vigneault/ A. Loblaw
   K. Sridhar

CCTG InterGroup OPEN TRIALS

11:05 am REC.3/PAPMET A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib and Savolitinib versus Sunitinib in Metastatic Papillary Renal Carcinoma.
   D. Heng

   W. Kassouf

CCTG InterGroup CLOSED TRIALS

11:15 am BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer
   W. Kassouf

PR.13/RADICALS/MRC PR.10 Radiotherapy and Androgen Deprivation In Combination After Local Surgery
   W. Parulekar

PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer
   S. North

PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only
   K.Chi

CCTG Approved TRIALS

11:35 am Phase II basket trial PM1/CAPTUR (Canadian Profiling and Targeted agent Utilization)
   K.Chi

BLC.2 (Alliance A031501): Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Placebo.
   K. Sridhar

BLC.3 (SWOG S1602): A Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer.
   W. Kassouf

IND234: Prostate cancer biomarker enrichment and treatment selection (pc-bets) study
   F. Vera-Badillo

12:00 pm LUNCH

continued on next page …
1:30 pm OPEN CUOG/CURC TRIALS

PRIME
Mast.
Hypothermia RCC
LIGAND
TITAN
ATLAS

2:00 pm DOG REPORTS/NEW PROPOSALS/GU DIRECTIONS

CSRI grant and GU retreat
Localized Prostate Cancer
Advanced Prostate Cancer
Bladder
Kidney
Testes
IND
Correlative Studies

3:45 pm Meeting Adjourned

3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED